The combined effect of IDA and glutaraldehyde on the properties of human erythrocytes

International Journal of Pharmaceutics

Volumn 220, Issue 1-2, 2001, Pages 43-51

  Szwarocka, Agnieszka ^a   Kowalczyk, Aleksandra ^a   Lubgan, Dorota ^a   Jóźwiak, Zofia ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Erythrocytes; ESR; Fluorescence; Glutaraldehyde; Idarubicin

Indexed keywords

CYTOSKELETON PROTEIN; GLUTARALDEHYDE; IDARUBICIN;

ARTICLE; CELL MEMBRANE; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; ELECTRON SPIN RESONANCE; ERYTHROCYTE; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; VISCOSITY;

ANTIBIOTICS, ANTINEOPLASTIC; CELL MEMBRANE; DISINFECTANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRON SPIN RESONANCE SPECTROSCOPY; ERYTHROCYTES; GLUTARAL; HUMANS; IDARUBICIN;

EID: 0035806332     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(01)00643-3     Document Type: Article

References (33)

1. Allen T.M. Liposomes. Opportunities in drug delivery. Drugs. 54:(S4):1997;8-14.
2. Ataullakhanov F.I., Kulikova E.V., Vitvitsky V.M. Reversible binding of anthracycline antibiotics to erythrocytes treated with glutaraldehyde. Biotechnol. Appl. Biochem. 24:1996;241-244.
3. Bartosz G., Leyko W. Aging of the erythrocyte. I. Increase in the microviscosity of cell interior as determined by the spin label method. Blut. 41:1980;131-136.
4. Berliner L.J. The spin-label approach to labeling membrane protein sulfhydryl groups. Ann. N. Y. Acad. Sci. 414:1983;153-161.
5. Butterfield, D.A., 1982. Spin labeling in disease. In Berliner, J. and Reuben, J. (Eds.) Biological Magnetic Resonance, Plenum Press, New York, pp. 1-78.
6. Butterfield, D.A., Palmieri, D.A., 1990. Spin-labeling studies of the interaction of 9-amino-1,2,3,4-tetrahydroacridine (THA), a proposed drug for the treatment of Alzheimer's disease, with erythrocyte membranes. Free Redic. Res. Commum. 9, 361-366.
7. Cersosimo R.J. Idarubicin: an anthracycline antineoplastic agent. Clin. Pharm. 11:1992;152-167.
8. DeLoach, J.R., Barton, C., 1981. Glutaraldehyde-treated carrier erythrocytes for organ targeting of methotrexate in dogs. Am. J. Vet. Res. 42, 1971-1974.
9. Dodge J., Mitchell C., Hanahan D. The preparation and chemical characteristics of hemoglobin-free ghost of human erythrocytes. Arch. Biochem. Biophys. 100:1963;119-130.
10. Dumas D., Gouin F., Viriot M.L., Stoltz J.F. Effect of glutaraldehyde on hemoglobin-dependent quenching of pyrene fluorescence. Application to oxygen diffusion in erythrocyte. Clin. Hemorheol. Microcirc. 17:1997;291-297.
11. Fukushima, T., Kawai, Y., Urasaki, Y., Yoshida, A., Ueda, T., Nakamura, T., 1994. Influence of idarubicinol on the antileukemic effect of idarubicin. Leukemia Res., 18, 943.
12. Fung, L.W., 1983. Analysis of spin-labeled erythrocyte membranes. Ann. NY Acad. Sci. 414, 162-168.
13. Gordon L.M., Looney F.D., Curtain C.C. Fatty-acid spin probe interactions with erythrocyte ghosts and liposomes prepared from erythrocyte ghost. J. Membr. Biol. 111:1989;155-168.
14. Grimm A., Madduri K., Ali A., Hutchinson C.R. Characterization of the Streptomyces peucetius ATCC 29050 genes encoding doxorubicin polyketide synthase. Gene. 151:(1-2):1994;1-10.
15. Hempel G., Haberland S., Schultze-Westhoff P., Mohling N., Blaschke G., Boos J. Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis. J. Chromatogr. B Biomed. Sci. Appl. 698:1997;287-292.
16. Iffert T., Soldan M., Moeller A., Maser E. Modulation of daunorubicin toxicity by liposomal encapsulation and use of specific inhibitors in vitro. Toxicology. 144:2000;189-195.
17. Kitao T., Hatori K. Erythrocyte entrapment of daunomycin by amphotericin B without hemolysis. Cancer Res. 40:1980;1351-1353.
18. Lejeune A., Moorjani M., Gicquaud C., Lacroix J., Poyet P., Gaudreault R.C. Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res. 14:1994;915-920.
19. Lowry O.H., Rosenbrough N.J., Farr A.L., Randal R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
20. Mandelli F., Petti M.C., Ardia A., Di Pietro N., Di Raimondo F., Ganzina F., Falconi E., Geraci E., Ladogana S., Latagliata R., Malleo C., Nobile F., Petti N., Rotoli B., Specchia G., Tabilio A., Resegotti L. A randomized clinical trial comparing idarubicin and cytarabine in the treatment of acute non-lymphoid leukemia. A multicentric study from the Italian co-operative group GIMENA. Eur. J. Cancer. 27:1991;750-755.
21. Matherne C.M., Satterfield W.C., asparini A., Tonetti M., Astroff A.B., Schmidt R.D., Rowe L.D., DeLoach J.R. Clinical efficacy and toxicity of doxorubicin encapsulated in glutaraldehyde-treated erythrocytes administered to dogs with lymphosarcoma. Am. J. Vet. Res. 55:1994;847-853.
22. Morse P.D. A comparison of the spin labels MAL-3 and TEMPAMINE for measuring the internal microviscosity of human erythrocytes. Biochim. Biophys. Acta. 844:1985;337-345.
23. Morse P.D. Determining intracellular viscosity from the rotational motion of spin labels. Methods Enzymol. 127:1986;239.
24. Noji, S., Taniguchi, S., Kon, H., 1991. An EPR study on erythrocyte deformability. Prog. Biophys. Mol. Biol. 55, 85-105.
25. Ondrias K. Use of electron spin resonance spectroscopy of spin labels for studying drug-induced membrane perturbation. J. Pharm. Biomed. Anal. 7:1989;649-675.
26. Reiffers, J., Huguet, F., Stoppa, A.M., Molina, L., Marut, G., Attl, M., Gastaut, J.A., Michallet, M., Lepeu, G., Broustet, A., Pris, J., Maraninchi, D., Hollard, D., Faberes, C., Mercier, M., Hurteloup, P., Danel, P., Tellier, Z., Berthaud, P., 1996. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia, 10, 389-395.
27. Sadzuka Y., Hirota S. Does the amount of an antitumor agent entrapped in liposomes influence its tissue distribution and cell uptake? Cancer Lett. 131:1998;163-170.
28. Sauerheber R.D., Lewis U.J., Esgate J.A., Gordon L.M. Effect of calcium insulin and growth hormone on membrane fluidity. A spin label study of rat adipocyte and human erythrocyte ghost. Biochim. Biophys. Acta. 597:1980;292-304.
29. Szwarocka A., Robak T., Krykowski E., Józwiak Z. Interaction of anthracyclines with human erythrocytes at hyperthermic temperature. Int. J. Pharm. 135:1996;167-176.
30. Szwarocka A., Fiet I., Józwiak Z. Idarubicin-induced changes in human erythrocyte membranes. Biomed. Lett. 56:1997;81-89.
31. Vogler W.R., Velez-Gracia E., Weiner R.S., Flaum M.A., Bartolucci A.A., Omura G.A., Gerber M.C., Banks P.L. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study. J. Clin. Oncol. 10:1992;1103-1111.
32. Wiernik P.H., Banks P.L.C., Case D.C. Jr, Arlin Z.A., Periman P.O., Todd M.B., Ritch P.S., Enck R.E., Weitberg A.B. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 79:1992;313-319.
33. Wyse J.W., Butterfield D.A. Electron spin resonance and biochemical studies of the interaction of the polyamine spermine with the skeletal network of proteins in human erythrocyte membranes. Biochim. Biophys. Acta. 941:1988;141-149.